Back to search

University of Ioannina

Η νόσος Gaucher στην Ελλάδα

Abstract

dc:description

Gaucher disease was initially described in 1882 by the French dermatologist Charles Ernest Gaucher. It is a rare lysosomal storage disease caused by the enzyme deficiency of glycocerebrosidase. Gaucher disease is inherited in an autosomal recessive manner. There are 3 subtypes of the disease according to age at onset, presence of neurological manifestations and clinical course. The diagnosis of Gaucher disease is based on the determination of glycocerebrosidase activity and is confirmed by molecular studies. Treatment approaches include supportive care, enzyme replacement therapy (ERT), substrate reduction therapy (SRT) or even allogeneic stem cell transplantation. In Greece there are 78 recorded cases of Gaucher disease (41 males and 37 females), including 69 Greek and 9 foreign patients. Among them, 70 (90%) had type 1,2 (3%) type 2 and 6 (8%) type 3 Gaucher disease. We studied 42 patients with respect to their genotype, clinical and laboratory features and response to treatment. Baseline laboratory parameters (complete blood count, serum lactate dehydrogenase, serum transaminase, ACP, chitotriosidase, serum immunoglobulin subclasses) did not differ significantly between patients who did or did not receive treatment. In a longitudinal study of the same parameters during ERT with imiglucerase, we observed improvement in the value of HgB, WBC, PLT, ACP and chito, which, however, was statistically significant only for ACP and chito value. All patients had hepatosplenomegaly. After 5 years of ERT there was a significant decrease of hepatosplenomegaly by 30% and 40% respectively. Patients with type 1 disease had no neurological manifestations, while all 4 studied patients with type 3 disease had neurological abnormalities. All patients reported bone pain, which resolved in those who received ERT. No abnormal imaging bone findings were recorded in 29% of the patients. Among patients with type 1 Gaucher disease who received ERT, 17% had objective improvement in abnormal imaging bone findings. A single patient had abnormal lung findings, while no cardiovascular symptoms or signs were recorded. Imiglucerase replacement therapy was offered in 28 patients (15 males and 13 females), all of whom experienced improvement in the quality of life. The initial dose was 60 IU/Kg every 2 weeks, which was reduced soon after treatment initiating; three, type 3, patients are in a dose of 120 IU/Kg every 2 weeks, because of neurological abnormalities (with significant improvement) or bone lesions. Two successful pregnancies were recorded in women undergoing ERT. Two patients received SRT with N-butyldeoxynojirimycin. Unfortunately there is no central registration of patients with Gaucher disease in Greece. A referral center, which could define the need of extensive follow-up and treatment is mandatory, particularly concentrate the need of lifelong therapy, which is extremely expensive. The wide spectrum of the problems of patients with Gaucher disease is faced by the Greek Gaucher and other Lysosomal Disorders “Solidarity”.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2007

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tsaftaridis, Panagiotis
  • Τσαφταρίδης, Παναγιώτης

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/20952

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tsaftaridis, Panagiotis; Τσαφταρίδης, Παναγιώτης. Η νόσος Gaucher στην Ελλάδα. University of Ioannina, 2007. http://hdl.handle.net/10442/hedi/20952